Joustra Wouter 4

What Happened

• Wouter Joustra, a director of enGene Therapeutics, was granted a derivative award of 31,000 shares on 2026-06-16. The reported acquisition price is $0.00, indicating an option/award rather than an open-market purchase or sale.

Key Details

• Transaction date: 2026-06-16; Form 4 filed: 2026-06-17 (timely).
• Transaction type/code: Grant/Award (Code A); derivative security (option/award) for 31,000 shares at $0.00.
• Shares owned after transaction: Not specified in the filing.
• Footnote: The award “vests fully on the earlier of (i) the first anniversary of the vesting commencement date (noted as June 9, 2026) or (ii) the registrant’s 2027 annual meeting of shareholders.” (Footnote F1)
• No sale or exercise reported—this is a grant, not a cash or cashless exercise.

Context

• This is a compensation-related grant to a director (not an open-market buy or sale). Grants and options are common for aligning director incentives; they do not represent immediate cash value until vested or exercised and sold.
• Because the award price is $0.00 and vesting conditions apply, there is no immediate proceeds or tax-withholding shown in the filing.